COVID-19 Infection and Idiopathic Membranous Nephropathy
NCT ID: NCT05691179
Last Updated: 2023-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
130 participants
OBSERVATIONAL
2022-12-10
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All subjects will be followed for three months with four visits at 1, 2 and 3 months. Then the investigator will compare the rate of replase of IMN in the two groups to evaluate the association of COVID-19 infection and replapse of IMN.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline
NCT00099567
Immunohematology in COVID-19 Patients: A Hospital-based Retrospective Cohort Study
NCT04932954
COVID-19 Infection and Multiple Myeloma
NCT04492371
Symptom Clusters and Risk Factors of COVID-19 Patients
NCT05556707
Greater Manchester CARDIOvascular Pathology in Immune-Mediated Inflammatory Diseases
NCT06600737
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 infection group
the patients with IMN and COVID-19 infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. estimated glomerular filtration rate (eGFR according to the CKD-EPI formula) ≥60 mL/min per 1.73 m2;
3. patients with a moderate risk of IMN.
Exclusion Criteria
2. the labarotary data two months before enrolement is absent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Pinggu District Hospital
OTHER
Beijing Fangshan District Liangxiang Hospital
OTHER
Beijing Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wenhu Liu
Professor Wenhu Liu
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Friedship Hospital
Beijing, Beijing Municipality, China
Beijing Pinggu Hospital
Beijing, Beijing Municipality, China
Beijing Liangxiang Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-P2-429-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.